Immunotherapy delays disease progression of high-grade meningiomas
Meningiomas are the most common primary tumors of the central nervous system. They are treated with surgery and radiation, but drug therapy is usually not effective against these tumors of the brain and spinal cord membranes. The immune checkpoint inhibitor pembrolizumab (Keytruda) showed efficacy against high-grade meningiomas in a clinical trial.
Materials provided by Massachusetts General Hospital. Note: Content may be edited for style and length.
Source link aaaaa
